American made: Companies continue to emphasize US manufacturing
Recent Q1 earnings calls from throughout the biopharmaceutical landscape have trended toward tariff talks and manufacturing reshoring. Companies continue to assuage investor concerns by both promoting their existing US manufacturing footprint, and by actively working … Read More